Skip to main content
Gut logoLink to Gut
. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

A K Azad Khan, D T Howes, J Piris, S C Truelove
PMCID: PMC1420362  PMID: 6105118

Abstract

Sulphasalazine is widely used in the maintenance treatment of ulcerative colitis but the optimum dose is not known. In the present study, 170 patients were allotted at random to three treatment groups, in which the daily dose was 1, 2 and 4 g respectively, and the trial period of treatment lasted for six months. A daily dose of 2 g was found to be much more efficacious than 1 g. A daily dose of 4 g was more efficacious than 2 g but at the price of fairly frequent symptomatic side-effects. Haematological abnormalities were observed at all dosage levels, but they occurred chiefly among the patients on 4 g daily. Both symptomatic and the haematological side-effects were usually associated with high concentrations of serum sulphapyridine and these high levels occurred chiefly among the slow acetylators. It is concluded that, for general use, a daily dose of 2 g sulphasalazine is satisfactory for the maintenance treatment of ulcerative colitis. If a patient does not do well on 2 g daily, it is worth trying a larger dose but in this case the patient's condition should be monitored by blood film, haemoglobin, MCV, and reticulocyte count.

Full text

PDF
232

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  2. BOETTIGER L. E., ENGSTEDT L., LAGERCRANTZ R., NYBERG A. THE OCCURRENCE OF HEINZ BODIES DURING AZULFIDINE TREATMENT OF ULCERATIVE COLITIS. Gastroenterologia. 1963;100:33–41. doi: 10.1159/000202343. [DOI] [PubMed] [Google Scholar]
  3. Collins J. R. Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis. South Med J. 1968 Apr;61(4):354–358. doi: 10.1097/00007611-196804000-00005. [DOI] [PubMed] [Google Scholar]
  4. DEVADATTA S., GANGADHARAM P. R., ANDREWS R. H., FOX W., RAMAKRISHNAN C. V., SELKON J. B., VELU S. Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960;23:587–598. [PMC free article] [PubMed] [Google Scholar]
  5. DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Das K. M., Eastwood M. A., McManus J. P., Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 1973 Aug;14(8):631–641. doi: 10.1136/gut.14.8.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. EVANS D. A., DAVISON K., PRATT R. T. THE INFLUENCE OF ACETYLATOR PHENOTYPE ON THE EFFECTS OF TREATING DEPRESSION WITH PHENELZINE. Clin Pharmacol Ther. 1965 Jul-Aug;6:430–435. doi: 10.1002/cpt196564430. [DOI] [PubMed] [Google Scholar]
  9. Evans D. A. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407. doi: 10.1136/jmg.6.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Franklin J. L., Rosenberg H. H. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine). Gastroenterology. 1973 Apr;64(4):517–525. [PubMed] [Google Scholar]
  11. GLOCK G. E., McLEAN P. Further studies on the properties and assay of glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of rat liver. Biochem J. 1953 Oct;55(3):400–408. doi: 10.1042/bj0550400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gabor E. P. Letter: Hemolytic anemia as adverse reaction to salicylazosulfapyridine. N Engl J Med. 1973 Dec 20;289(25):1372–1372. doi: 10.1056/NEJM197312202892514. [DOI] [PubMed] [Google Scholar]
  13. HUGHES H. B., BIEHL J. P., JONES A. P., SCHMIDT L. H. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc. 1954 Aug;70(2):266–273. doi: 10.1164/art.1954.70.2.266. [DOI] [PubMed] [Google Scholar]
  14. Hansson K. A. Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973 May;10(2):153–155. [PubMed] [Google Scholar]
  15. Hansson K. A., Sandberg M. Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973 Mar;10(1):87–92. [PubMed] [Google Scholar]
  16. Jamshidi K., Arlander T., Garcia M. C., Windschitl H. W., Swaim W. R. Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis. Minn Med. 1972 Jun;55(6):545–548. [PubMed] [Google Scholar]
  17. LENNARD-JONES J. E., LONGMORE A. J., NEWELL A. C., WILSON C. W., JONES F. A. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960 Sep;1:217–222. doi: 10.1136/gut.1.3.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. MOERTEL C. G., BARGEN J. A. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Ann Intern Med. 1959 Nov;51:879–889. doi: 10.7326/0003-4819-51-5-879. [DOI] [PubMed] [Google Scholar]
  19. MORRISON L. M. Results of treatment of ulcerative colitis with salicylazosulfapyridine. Gastroenterology. 1952 May;21(1):133–138. [PubMed] [Google Scholar]
  20. Miller B., Sandrock K., Goebel K. M., Englhardt A., Martini G. A. Untersuchungen zum Mechanismus der Hämiglobinbildung durch Salicylazosulfapyridin (Azulfidine. Verh Dtsch Ges Inn Med. 1972;78:698–700. [PubMed] [Google Scholar]
  21. Pounder R. E., Craven E. R., Henthorn J. S., Bannatyne J. M. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis. Gut. 1975 Mar;16(3):181–185. doi: 10.1136/gut.16.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. SPRIGGS A. I., SMITH R. S., GRIFFITH H., TRUELOVE S. C. Heinz-body anaemia due to salicylazosulphapyridine. Lancet. 1958 May 17;1(7029):1039–1042. doi: 10.1016/s0140-6736(58)92005-1. [DOI] [PubMed] [Google Scholar]
  23. Sandberg M., Hansson K. A. Determination of salicylazosulphapyridine in biological materials. Acta Pharm Suec. 1973 May;10(2):107–110. [PubMed] [Google Scholar]
  24. Schröder H., Evans D. A. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972 Apr;13(4):278–284. doi: 10.1136/gut.13.4.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. TRUELOVE S. C., RICHARDS W. C. Biopsy studies in ulcerative colitis. Br Med J. 1956 Jun 9;1(4979):1315–1318. doi: 10.1136/bmj.1.4979.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. TRUELOVE S. C., WATKINSON G., DRAPER G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J. 1962 Dec 29;2(5321):1708–1711. doi: 10.1136/bmj.2.5321.1708. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES